Synthesis, crystal structure, studies in solution and cytotoxicity of two new fluorescent platinum(II) compounds containing anthracene derivatives as a carrier ligand

Two new cytotoxic fluorescent platinum(II) compounds, cis-[Pt(A9opy)Cl2] (1) and cis-[Pt(A9pyp)(DMSO)Cl2] (2),have been designed, synthesized, and characterized by IR, 1H NMR, and 195Pt NMR spectroscopy; electrospray ionization mass spectrometry (ESI-MS); and single-crystal X-ray diffraction. The carrier ligands selected for thesynthesis of these fluorescent platinum(II) compounds are E-2-[1-(9-anthryl)-3-oxo-3-prop-2-enylpyridine] (abbreviatedas A9opy) and E-1-(9-anthryl)-3-(2-pyridyl)-2-propenone (abbreviated as A9pyp). The compound cis-[Pt(A9opy)Cl2](1) comprises a peculiar cis-platinum(II) organometallic compound, in which the platinum(II) ion is bound to the photoisomerizable carbon-carbon double bond of the carrier ligand. The effects of the metal-ion coordination on the photoisomerization of the carbon-carbon double bond of the ligand have been studied. In contrast, the carrier ligand A9pyp used for the synthesis of the cis-[Pt(A9pyp)(DMSO)Cl2] compound (2) does not undergo such anisomerization process and remains in the E conformation, while coordinated to the platinum(II) ion through the nitrogen of the pyridine ring. In addition to the synthesis and characterization, solution studies of both compounds have also been performed in detail, including NMR and ESI-MS spectroscopy. Moreover, a high degree of cytotoxicactivity of compound 1 was found, as compared to cisplatin and its corresponding platinum-free molecule, in a series of human tumor cell lines. Compound 2 was also found to be highly active against these cell lines but appeared less active compared to the platinum-free molecule.     

7-Methylguanine: protonation, formation of linkage isomers with trans-(NH3)2Pt(II), and base pairing properties

Three protonated forms of 7-methylguanine (7-MeGH, 1) with different counter ions, [7-MeGH(2)]X (X = NO(3), 1a; ClO(4), 1b; BF(4), 1c) and two Pt(II) complexes, trans-[Pt(NH(3))(2)(7-MeGH-N9)(2)](ClO(4))(2) (4) and trans-[Pt(NH(3))(2)(7-MeGH-N9)(7-MeGH-N3)](ClO(4))(2)·3H(2)O (5) are described and their X-ray crystal structures are reported. 1a-1c form infinite ribbons via pairs of intermolecular hydrogen bonds between N1H···O6 and N3···N2H(2) sites, with anions connecting individual ribbons, thereby generating extended sheets. 4 and 5 do not display unusual features, except that 5 represents a rare case of a bis(nucleobase) complex of Pt(II) in which linkage isomers occur. Unlike in a previously reported compound, [Pt(dien)(7-MeGH-N9)](NO(3))(ClO(4)), the Pt coordination planes and the 7-MeGH planes are not coplanar in 4 and 5. The hydrogen bonding behaviour of 7-MeGH, free and when platinated at N9 (complex 4), was studied in Me(2)SO-d(6). It revealed the following: (i) there is no detectable self-association of 1 in Me(2)SO solution. (ii) 1 and 1-methylcytosine (1-MeC) form Watson-Crick pairs. (iii) 4 does not self-associate. (iv) 4 associates with 1-MeC in the Watson-Crick fashion. (v) 4 and 1 interact in solution, but no model can be proposed at present. (vi) Remarkable interaction shifts between 4 and 1 occur when NH(3) is liberated from trans-(NH(3))(2)Pt(II) to give NH(4)(+) in Me(2)SO-d(6). Feasible models, which imply the presence of deprotonated 7-MeG(-) species are proposed. Finally, DFT calculations were carried out to qualitatively estimate the effect of 7-MeGH acidity in [Pt(dien)(7-MeGH-N9)](2+) in dependence of the dihedral angle between the Pt coordination plane and the nucleobase.     

Encapsulation of metal cations and anions within the cavity of bis(1,4,7-triazacyclononane) receptors

The synthesis and characterisation of a new bis([9]aneN3) ligand (L4) containing two [9]aneN3 macrocyclic moieties separated by a 2,6-dimethylenepyridine unit is reported. A potentiometric and 1H NMR study in aqueous solution reveals that ligand protonation occurs on the secondary amine groups and does not involve the pyridine nitrogen. The coordination properties toward Cu(II), Zn(II), Cd(II) and Pb(II) were studied by means of potentiometric and UV spectrophotometric measurements. The ligand can form mono- and binuclear complexes in aqueous solution. In the 1 : 1 complexes, the metal is sandwiched between the two [9]aneN3 moieties and the pyridine N-donor is coordinated to the metal, as actually shown by the crystal structure of the compound [ZnL4](NO3)2.CH3NO2. L4 shows a higher binding ability for Cd(II) with respect to Zn(II), probably due to a better fitting of Cd(II) ion inside the cavity generated by the two facing [9]aneN3 units. The formation of binuclear complexes is accompanied by the assembly of OH-bridged M2(OH)x (x = 1-3) clusters inside the cavity defined by the two facing [9]aneN3 units, and pyridine is not involved in metal coordination. A potentiometric and (1)H NMR study on the coordination of halogenide anions by L4 and its structural analogous L3 in which the two [9]aneN3 units are separated by a shorter quinoxaline linkage, shows that bromide is selectively recognised by L4, while chloride is selectively bound by L3. Such a behaviour is discussed in terms of dimensional matching between the spherical anions and the cavities generated by the two [9]aneN3 units of the receptors.     

Metal-metal interactions in thallium(I)/platinum(II) compounds involving a chelating dicarbene and various auxiliary ligands

Reaction of Tl(I)NO(3) and (C(4)H(10)N(4))Pt(II)(mnt) or (C(4)H(10)N(4))Pt(II)(dmg-H) [mnt = maleonitriledithiolate, dmg-H = dimethylglyoximate dianion] in dilute, aqueous KOH yielded adducts of Tl(I) and the conjugate bases of the platinum(II) compounds. The compound Tl(I)[(C(4)H(9)N(4))Pt(II)(dmg-H)].5H(2)O forms as dimers with close Tl(I)...Pt(II) separations of 3.0843(5) A, while Tl(I)[(C(4)H(9)N(4))Pt(II)(mnt)] has much longer Tl(I)...Pt(II) separations of 3.4400(2) A and forms loosely associated, helical coordination polymers. The new compounds are compared with the red and yellow polymorphs of Tl(I)[(C(4)H(9)N(4))Pt(II)(CN)(2)], and the influences of crystal packing forces, Coulombic interactions, and hydrogen bonding on supramolecular structures and Tl(I)...Pt(II) separations are discussed.     

Studies of bicarbonate binding by dinuclear and mononuclear Ni(II) complexes

Bicarbonate ion reacts with the dinuclear nickel(II) complex containing the taec ligand (taec = N,N',N' ',N' '-tetrakis(2-aminoethyl)-1,4,8,11-tetraazacyclotetradecane) in buffered aqueous solution to form the mu-eta(2),eta(2)-carbonate complex with a large effective binding constant for bicarbonate ion, log K(B) = 4.39 at pH = 7.4. In contrast, the dinuclear nickel(II) complex containing the o-xyl-DMC(2) ligand (o-xyl-DMC(2) = alpha,alpha'-bis(5,7-dimethyl-1,4,8,11-tetraazacyclotetradecan-6-yl)-o-xylene) does not react with bicarbonate or carbonate ion in aqueous solution. In propylene carbonate, the reaction of [Ni(2)(o-xyl-DMC(2))](4+) with bicarbonate proceeds rapidly to form the mu-eta(1),eta(1)-carbonate complex. The structure of this carbonate complex has been determined by an X-ray diffraction study that confirms the mu-eta(1),eta(1)-carbonate binding mode. A mononuclear analogue of [Ni(2)(taec)](4+), [Ni(2,3,2-tetraamine)](2+) does not form a detectable mononuclear or dinuclear product with bicarbonate ion in aqueous solution, but [NiDMC](2+) (DMC = 5,7-dimethyl-1,4,8,11-tetraazacyclotetradecane) reacts slowly with carbonate ion in aqueous solution to form a 2:1 complex.     

Pd(II) Binding Strength of a Novel Ambidentate Dipeptide-Hydroxypyridinonate Ligand: A Solution Equilibrium Study

A novel ambidentate dipeptide conjugate (H(L1)) containing N-donor atoms of the peptide part and an (O,O) chelate at the hydroxypyridinone (HP) ring is synthesized and characterized. It is hoped that this chelating ligand can be useful to obtain multitargeted Co(III)/Pt(II) dinuclear complexes with anticancer potential. The Pd(II) (as a Pt(II) model but with faster ligand exchange reactions) binding strength of the ligand was studied in an aqueous solution with the combined use of pH-potentiometry and NMR. In an equimolar solution, (L1)⁻ was found to bind Pd(II) via the terminal amino and increasing number of peptide nitrogens of the peptide backbone over a wide pH range. At a 2:1 Pd(II) to ligand ratio, the presence of [Pd₂H_–x(L1)] (x = 1–4) species, with high stability and with the coordination of the (O,O) chelating set of the ligand, was detected. The reaction of H(L1) with [Co(tren)]³⁺ (tren = tris(2-aminoethyl)amine) indicated the exclusive binding of (L1)⁻ via its (O,O) donor atoms to the metal unit, while treatment of the resulting Co-complex with Pd(II) afforded the formation of a Co/Pd heterobimetallic complex in solution with an (NH₂, N_amide) coordination of Pd(II). Shortening the peptide backbone in H(L1) by one peptide unit compared to the structurally similar ambidentate chelator consisting of three peptide bonds resulted in the slightly more favorable formation of the N-coordinated Pd(II) species, allowing the tailoring of the coordination properties.     

17 e- rhenium dicarbonyl CO-releasing molecules on a cobalamin scaffold for biological application

Cyanocobalamin (B(12)) offers a biocompatible scaffold for CO-releasing 17-electron dicarbonyl complexes based on the cis-trans-[Re(II)(CO)(2)Br(2)](0) core. A Co-C≡N-Re conjugate is produced in a short time and high yield from the reaction of [Et(4)N](2)[Re(II)Br(4)(CO)(2)] (ReCORM-1) with B(12). The B(12)-Re(II)(CO)(2) derivatives show a number of features which make them pharmaceutically acceptable CO-releasing molecules (CORMs). These cobalamin conjugates are characterized by an improved stability in aqueous aerobic media over the metal complex alone, and afford effective therapeutic protection against ischemia-reperfusion injury in cultured cardiomyocytes. The non-toxicity (at μM concentrations) of the resulting metal fragment after CO release is attributed to the oxidation of the metal and formation in solution of the ReO(4)(-) anion, which is among the least toxic of all of the rare inorganic compounds. Theoretical and experimental studies aimed at elucidating the aqueous chemistry of ReCORM-1 are also described.     

Platinum and Palladium Complexes Bearing New (1R,2R)‐(–)‐1,2‐Diaminocyclohexane (DACH)‐Based Nitrogen Ligands: Evaluation of the Complexes Against L1210 Leukemia

The reaction of (1R,2R)‐(–)‐1,2‐diaminocyclohexane ( 1 ) [DACH] with the aldehyde (1R)‐(–)‐myrtenal ( 2 ) in MeOH afforded the bidentate diimine ligand, (1R,2R)‐(–)‐N¹,N²‐bis{(1R)‐(–)myrtenylidene}‐1,2‐diaminocyclohexane ( 3 ) in a high yield. Reduction of 3 using LiAlH₄ led to the formation of the desired ligand ( 4 ) (1R,2R)‐(–)‐N¹,N²‐bis{(1R)‐(–)myrtenyl}‐1,2‐diaminocyclohexane. Treatment of compound 4 with K₂PtCl₄ or K₂PdCl₄ yielded the corresponding platinum(II) and palladium(II) complexes, Pt‐5 and Pd‐6 , respectively. The reaction of compound 3 with K₂PtCl₄ gave the diimine complex Pt‐7 . The cytotoxic activity of the complexes Pt‐5 , Pd‐6 and Pt‐7 was tested and compared to the approved drugs, cisplatin ( Cis ‐Pt ) and oxaliplatin ( Ox‐Pt ). The complexes ( Pt‐5 , Pd‐6 and Pt‐7 ) inhibit L1210 cell line proliferation with an IC₅₀ of 0.6, 4.2, and 0.7 μL, respectively as evidenced by measuring thymidine incorporation.     

Reactions of halogens with Pt(II) complexes of N-alkyl- and N,N-dialkyl-N'-benzoylthioureas: oxidative addition and formation of an I2 inclusion compound

The treatment of cis-[Pt(II)(L(1a/b)-S,O)2] complexes of N,N-diethyl- (HL(1a)) and N,N-di(n-butyl)-N'-benzoylthiourea (HL(1b)) with I2 or Br2 in chloroform, leads to rapid oxidative addition to yield several geometric isomers of [Pt(IV)(L-S,O)(2)X(2)](X = I, Br); the reactions can be monitored by (195)Pt NMR and UV-visible spectrophotometry. The products cis-[Pt(IV)(L(1a)-S,O)2I2] and cis-[Pt(IV)(L(1a)-S,O)2Br2], which have been isolated and structurally characterized, are the first-reported crystal structures of complexes of Pt(iv) with this class of ligand. Molecules of 6 pack such that the I-Pt-I axes are essentially aligned, with unusually close nearest-neighbour iodide contacts (3.553(1)A). These short II intermolecular interactions lead to infinite chains of weakly connected molecules in crystals of the compound. No such interactions are evident in the corresponding crystals of . Reaction of the Pt(II) complex of N-propyl-N'-benzoylthiourea (H2L(2a))cis-/trans-[Pt(II)(H2L(2a)-S)2Br2] with Br2 also results in oxidative addition, to yield trans-Pt(IV)(H2L(2a)-S)2Br4. By contrast, treatment of cis-/trans-[Pt(II)(H2L(2a)-S)2I2] with I2 does not lead to an oxidative addition product, yielding instead an interesting iodine inclusion compound of Pt(II), trans-[Pt(II)(H2L(2a)-S)2I2.I2. In 8, short intermolecular II distances of 3.453(1)A between I2 and coordinated iodide ions in trans-[Pt(II)(H(2)L(2a)-S)(2)I(2)] molecules, result in infinite chains of weakly linked trans-[Pt(II)(H2L(2a)-S)2I2]...I2 groups in the lattice. However, the empirically estimated bond order of 0.75 for the included I2 molecules does not support the possible existence of discrete tetraiodide ions (I4(2-)) in the lattice of compound 8.     

1-(2-Picolyl)-substituted 1,2,3-triazole as novel chelating ligand for the preparation of ruthenium complexes with potential anticancer activity

The 1,4-disubstituted 1,2,3-triazole ligand prepared by click chemistry 1-(2-picolyl)-4-phenyl-1H-1,2,3-triazole (ppt) was investigated as novel chelating ligand for Ru(II) complexes with potential antitumor activity. The preparation and structural characterization, mainly by NMR spectroscopy in solution and by X-ray crystallography in the solid state, of four new Ru(II) complexes is reported: two isomeric Ru-dmso compounds, trans,cis-[RuCl(2)(dmso-S)(2)(ppt)] (1) and cis,cis-[RuCl(2)(dmso-S)(2)(ppt)] (2), and two half-sandwich Ru-[9]aneS(3) coordination compounds, [Ru([9]aneS(3))(dmso-S)(ppt)][CF(3)SO(3)](2) (3) and [Ru([9]aneS(3))Cl(ppt)][CF(3)SO(3)] (4). In all compounds ppt firmly binds to ruthenium in a bidentate fashion through the pyridyl nitrogen atom and the triazole N2, thus forming a puckered six-membered ring. The chemical behavior in aqueous solution of the water-soluble complexes 3 and 4 was studied by UV-Vis and NMR spectroscopy and compared to that of the previously described organometallic analogue [Ru(η(6)-p-cymene)Cl(ppt)][Cl] (5) in view of their potential antitumor activity. Compounds 3-5 were tested also in vitro for cytotoxic activity against two human cancer cell lines, one sensitive and one resistant to cisplatin, in comparison with cisplatin. Compound 4, the one that aquates faster, was found to be more cytotoxic than cisplatin against human lung squamose carcinoma cell line (A-549).     

Synthesis and DNA-binding properties of cationic 2,2':6',2' '-terpyridineplatinum(II) complexes containing 1,2- and 1,7-dicarba-closo-dodecaborane(12)

The first examples of DNA metallointercalators containing a dicarba-closo-dodecaborane(12) (carborane) moiety are presented. Treatment of the labile platinum(II) complex [Pt(OTf)(terpy)](+) (terpy = 2,2':6',2' '-terpyridine) with the 1,2-carborane monothiol derivatives 1-HS(CH(2))(n)-1,2-C(2)B(10)H(11) (n = 0, 1) or the novel 1,7-carborane ligand, 1-HSCH(2)-1,7-C(2)B(10)H(11), affords the stable, brightly colored species [Pt(1-S(CH(2))(n)-1,Z-C(2)B(10)H(11))(terpy)](+) (Z = 2, n = 0, 1; Z = 7, n = 1) in good yield and purity. Preliminary DNA-binding experiments with calf-thymus DNA indicate an intercalative interaction by the platinum(II) complexes at high r(f) values.     

Complexes of platinum(II) containing neutral and deprotonated 9-methyladenine. Synthesis, x-ray structures, and NMR studies on the cyclic trimer cis-[L2Pt[9-MeAd([bond]H)]]3(NO3)3 and the Dinuclear cis-[L2Pt(ONO2)[9-MeAd([bond]H)]PtL2](NO3)2 (L = PMePh2)

The dinuclear hydroxo complex cis-[L(2)Pt(mu-OH)](2)(NO(3))(2) (L = PMePh(2), 1), in CH(2)Cl(2), CH(3)CN, or DMF solution, deprotonates the NH(2) group of 9-methyladenine (9-MeAd) to give the complex cis-[L(2)Pt[9-MeAd(-H)]](3)(NO(3))(3), 2, which was isolated in good yield. The X-ray structure shows that the nucleobase binds symmetrically the metal centers through the N(1),N(6) atoms forming a cyclic trimer with Pt...Pt distances in the range 5.202(1)-5.382(1) A. Dissolution of 2 in DMSO or DMF determines the partial (or total) dissociation of the cyclic structure to form several fragments. A multinuclear NMR analysis of the resulting mixture supports the presence of the mononuclear species cis-[L(2)Pt[9-MeAd(-H)]](+), 3, in which the deprotonated nucleobase chelates the metal center with the N(6),N(7) atoms. Addition of a stoichiometric amount of the nitrato complex cis-[L(2)Pt(ONO(2))(2)] (L = PMePh(2), 4) to a DMSO or DMF solution of 2 affords quantitatively the diplatinated compound cis-[L(2)Pt(ONO(2))[9-MeAd(-H)]PtL(2)](NO(3))(2), 5. The single-crystal X-ray analysis shows that the adenine behaves as a tridentate ligand bridging two cis-L(2)Pt units at the N(1) and N(6),N(7) sites, respectively [Pt(1)-N(1) = 2.109(5) A, Pt(2)-N(6) = 2.095(7) A, Pt(2)-N(7) = 2.126(7) A]. The N(1)-bonded metal center completes the coordination sphere through an oxygen atom of a nitrate group, and its coordination plane is arranged orthogonally with respect the second one. The Pt-O distance [2.109(5) A] is similar to those found in the nitrato complex 4 [2.110 A, average]. The related complex cis-[[L(2)Pt(ONO(2))](2)(9-MeAd)](NO(3))(2), 6, containing the neutral adenine platinated at the N(1),N(7) atoms, was isolated and its stability in solution investigated by NMR spectroscopy. In DMSO, 6 undergoes decomposition forming a mixture of the species 4, 5, and the adenine mono- and bis-adducts cis-[L(2)Pt(9-MeAd)(DMSO)](2+), 7, and cis-[L(2)Pt(9-MeAd)(2)](2+), 8, respectively. This last complex, quantitatively formed upon addition of 9-MeAd (Pt/adenine = 1:2) to the mixture, was also isolated and characterized.     

Iodination of cisplatin adduct of Vitamin B12 [{B12}-CN-{cis-PtCl(NH3)2}]

The cisplatin adduct of vitamin B₁₂, [{B₁₂}-CN-{cis-PtCl(NH₃)₂}]⁺ (1), reacts with iodide in aqueous solution to form [{B₁₂}-CN-{trans-PtI₂(NH₃)}] (3) in good yield. Mono-substitution of chloride was not observed since a subsequent replacement of one NH₃ by a second iodide is very fast as compared to the Cl⁻ → I⁻ exchange. The same reaction conditions allowed to introduce radioiodide ¹³¹I. Vitamin B₁₂ can therefore be labeled with radionuclides via binding to the Pt(II) center.     

Cytotoxic activity of two polyaspartamide‐ based monoamineplatinum(II) conjugates against the HeLa cancer cell line

In this screening study in vitro, two polymer‐conjugated, square‐planar platinum(II) complexes bound to the carrier via a single primary amine ligand were tested for antineoplastic activity against the HeLa human cervical epithelioid carcinoma cell line. In the first of these conjugates, 1‐Pt , the spacer connecting the metal complex with the carrier backbone is a short oligo(ethylene oxide) segment, whereas a long poly(ethylene oxide) chain represents the spacer unit in the second conjugate, 2‐Pt . IC₅₀ data, expressed as conjugate concentration at 50% cell growth inhibition, are 48 µg Pt ml⁻¹ for 1‐Pt and 120 µg Pt ml⁻¹ (estimated) for 2‐Pt , the long tether in the latter conjugate presumably causing retarded enzymic release and lysosomal membrane crossing of the monomeric complex. The IC₅₀ value of 1‐Pt is close to that (44 µg Pt ml⁻¹) of a similar conjugate of an earlier investigation, 3‐Pt , in which the metal is chelated by two carrier‐attached, cis‐oriented amino groups in conformance with the ligand arrangement in cisplatin. It thus appears that, in the carrier‐bound state, both monoamine‐ and cis‐diamine‐coordinated platinum(II) complexes of suitable structures may well show similar biological performance patterns. Copyright­© 1999 John Wiley & Sons, Ltd.     

Platinum complexes of diazo ligands. Studies of regioselective aromatic ring amination, oxidative halogen addition and reductive halogen elimination reactions

2-(Arylazo)pyridine ligands, L1a-1c react with the salt K2[PtCl4] to give the mononuclear complexes [PtCl2(L1)](1), which readily react with ArNH2 to yield the monochloro complexes of type [PtCl(L2)](HL2= 2-[(2-(arylamino)phenyl)azo]pyridine)(2) via regioselective ortho-amine fusion at the pendent aryl ring of coordinated L1. Oxidative addition of the electrophiles Y2(Y = Cl, Br, I) to the square-planar platinum(II) complex, has led to syntheses of the corresponding octahedral platinum(IV) complexes, [PtY3(L2)](3) in high yields. Ascorbate ion reductions of the platinum(IV) complexes, , resulted in reductive halogen elimination to revert to the platinum(II) complexes almost quantitatively. Isolation of products and X-ray structure determination of the representative complexes followed all these chemical reactions. In crystal packing, the compound [PtCl2(L1c)](1c) forms dimeric units with a Pt...Pt distance of 3.699(1) A. In contrast, the crystal packing of 2b revealed that the molecules are arranged in an antiparallel fashion to form a noncovalent 1D chain to accommodate pi(aryl)-pi(pyridyl) and Pt-pi(aryl) interactions. Notably, the oxidation of [Pt(II)Cl(L2a)](2a) by I2 produced a mixed halide complex [Pt(IV)ClI2(L2a)](5), which, in turn, is reduced by ascorbate ion to produce [Pt(II)I(L2a)] with the elimination of ClI. All the platinum(II) complexes are brown, the platinum(IV) complexes, on the other hand, are green. Low-energy visible range transitions in the complexes of the extended ligand [L2]- are ascribed to ligand basedpi-pi* transitions. Cyclic voltammetric behaviour of the complexes is reported.     

Atropisomerization, C-H activation, and dissociative substitution at some biphenyl platinum(II) complexes

The reaction of 2,2'-dilithiumbiphenyl with cis-[PtCl(2)(SEt(2))(2)] at -10 degrees C in diethyl ether not only leads to the main product [Pt(2)(micro-SEt(2))(2)(bph)(2)], containing the planar 2,2'-biphenyl dianion (bph(2)(-)), but also forms a new dinuclear platinum(II) compound of formula [Pt(2)(micro-SEt(2))(2)(Hbph)(4)], 1a (Hbph(-) = eta(1)-biphenyl monoanion), in which each metal is in a square-planar environment. NMR spectroscopy and molecular mechanics (MMFF) calculations were used to characterize 1a. The results suggest that the favored conformation for the four Hbph biphenyl groups is alphabetabetaalpha. In chloroform solution, 1a undergoes atropisomerization to 1b (alphabetaalphabeta) (k(is) = 1.03 x 10(-)(4) s(-)(1), at 298 K) that subsequently cyclometalates (k(obs) = 4.48 x 10(-)(6) s(-)(1), at 298 K) to yield [Pt(2)(micro-SEt(2))(2)(bph)(2)] and biphenyl. Both processes, atropisomerization and C-H activation, presumably involve preliminary thioether bridge splitting. The dinuclear complex 1a has been shown to be a versatile and useful precursor to a variety of mononuclear eta(1)-biphenyl platinum(II) complexes. By reaction with diethyl sulfide, dimethyl sulfoxide, or with rigid dinitrogen containing ligands, such as 2,2'-bipyridine or 1,10-phenanthroline, complexes cis-[Pt(Hbph)(2)(dmso)(2)] 3, cis-[Pt(Hbph)(2)(SEt(2))(2)] 4, [Pt(Hbph)(2)(bpy)] 5, and [Pt(Hbph)(2)(phen)] 6 were obtained, respectively. The crystal structures of compounds 5 and 6 were determined. Only the head-to-tail isomer of these compounds was recognized in the solid state and in solution, where restricted rotation around the Pt-C bond prevents interconversion to the head-to-head form. A detailed kinetic study of ligand (dmso) exchange and substitution (by 2,2'-bipyridine and 1,10-phenanthroline) has been performed on complex 3 in CDCl(3) and toluene-d(8) by (1)H NMR magnetization transfer experiments, and in toluene by UV/vis spectroscopy, respectively. The rates of both processes show no dependence on ligand concentration, the rate of ligand substitution being in reasonable agreement with that of ligand exchange at the same temperature. The kinetics are characterized by largely positive entropies of activation. The results are consistent with a dissociative mode of activation analogous to the pattern already found for compounds with a similar [Pt(C,C)(S,S)] set of coordinating ligands. The role of ML(3) d(8) T-shaped 14-electron species, as elusive reaction intermediates or structurally characterized compounds, is discussed.     

The chemistry of dinuclear analogues of the anticancer drug cisplatin. A DFT/CDM study

The mechanism of the formation of dinuclear platinum(II) mu-hydroxo complexes from cisplatin hydrolysis products, their interconversion, decomposition, and reactions with biomolecules has been explored using a combined DFT/CDM approach. All activation barriers for the formation of [cis-{Pt(NH(3))(2)(X)}-(mu-OH)-cis-{Pt(NH(3))(2)(Y)}](n)()(+) (X, Y = Cl, OH(2), OH) via nucleophilic attack of a hydroxo complex on an aqua complex are lower than the activation barriers for cisplatin hydrolysis. Considering therapeutic Pt(II) concentrations in tumors, however, only the reaction between two molecules of cis-[Pt(NH(3))(2)(OH(2))(OH)](+) (E) yielding [cis-{Pt(NH(3))(2)(OH(2))}-(mu-OH)-cis-{Pt(NH(3))(2)(OH)}](2+) (5) remains kinetically superior to cisplatin hydrolysis. 5 is strongly stabilized by intramolecular hydrogen bonding between the terminal aqua and hydroxo ligands, resulting in an unusually high pK(a) of 5 and a low pK(a) of its conjugate acid. Unimolecular cyclization of 5 yields the dimers [cis-{Pt(NH(3))(2)}(mu-OH)](2)(2+) (7a with antiperiplanar OH groups and 7b with synperiplanar OH groups). The electronic structure of several diplatinum(II) complexes has been analyzed to clarify whether there are metal-metal interactions. The overall reactivity to guanine (Gua) and dimethyl sulfide (Met, representing the thioether functional group of methionine) increases in the order 5 < 7a approximately 7b < mononuclear complexes, whereas the kinetic selectivity to Gua relative to Met increases in the order 7a approximately 5 < 7b approximately monocationic mononuclear complexes < dicationic mononuclear complex. The results of this work (i) help assess whether dinuclear metabolites play a role in cisplatin chemotherapy, (ii) elucidate the toxicity and pharmacological inactivity of [cis-{Pt(NH(3))(2)}(mu-OH)](2)(2+), and (iii) suggest future investigations of dinuclear anticancer complexes that contain one mu-hydroxo ligand.     

Synthesis and characterization of bioorganometallic conjugates composed of NCN-pincer platinum(II) complexes and uracil derivatives

The conjugation of the NCN-pincer platinum(II) complexes as an oraganometallic compound and the uracil derivatives as a nucleobase was demonstrated to give the corresponding bioorganometallics. The NCN-pincer ligands bearing the 6-ethynyl-1-octyluracil, 5-ethynyl-1-octyluracil, and the furanopyrimidine moiety were synthesized. In a crystal state, the NCN-pincer ligand bearing the 6-ethynyl-1-octyluracil moiety was found to form a hydrogen-bonded dimer through intermolecular hydrogen bonds between the uracil moieties, which was connected through π-π interaction between the uracil and benzene moieties of the NCN-pincer ligand. The reaction of the NCN-pincer ligand bearing the 6-ethynyl-1-octyluracil moiety with [Pt(tolyl-4)₂(SEt₂)]₂ led to the formation of the NCN-pincer platinum(II) complex bearing the 6-ethynyl-1-octyluracil moiety. The NCN-pincer platinum(II) complex bearing the furanopyrimidine moiety was obtained by the reaction of the NCN-pincer ligand bearing the furanopyrimidine moiety with [Pt(tolyl-4)₂(SEt₂)]₂. The single-crystal X-ray structure determination of the NCN-pincer platinum(II) complex bearing the furanopyrimidine moiety revealed the formation of the furanopyrimidine ring and the π stack dimer between the furanopyrimidine and benzene moieties of the NCN-pincer ligand in the crystal packing. The NCN-pincer platinum(II) complexes bearing the 6-ethynyl-1-octyluracil moiety or the furanopyrimidine moiety exhibited emission in both solution and solid states.     

On the competition of the purine bases,functionalities of peptide side chains,and protecting agents for the coordination sites of dicationic cisplatin derivatives

The Pt-L bond energies of simple triammineplatinum(II) complexes, [Pt(NH(3))(3)L](2+), with oxygen-, nitrogen-, and sulfur-containing donor ligands L have been predicted and rationalized using density functional theory. The ligands L have been chosen as models for functionalities of peptide side chains, for sulfur-containing protecting agents, and for adenine and guanine sites of the DNA as the ultimate target of platinum anticancer drugs. Calculation of the Pt-L bond energy in [Pt(NH(3))(3)L](2+) reveals that the soft metal center of triammineplatinum(II) prefers N ligands over S ligands. This remarkable result has been discussed in light of several interpretations of the hard and soft acids and bases principle. The concept of orbital-symmetry-based energy decomposition has been employed for the determination of the contributions from sigma and pi orbital interactions, electrostatics, and intramolecular hydrogen bonding to the Pt-L bond energy. The calculations show that considerable differences in the bond energies of the triammineplatinum(II) complexes with N-heterocycles such as 1-methylimidazole, 9-methyladenine, and 9-methylguanine arise from electrostatics rather than from orbital interactions. Surprisingly, the net stabilization by hydrogen bonding between the (Pt)N-H group and the oxygen of 9-methylguanine is as weak as the intramolecular hydrogen bond in the aqua complex [Pt(NH(3))(3)(H(2)O)](2+), challenging the common hypothesis that DNA-active anticancer drugs require carrier ligands with N-H functionalities because of their hydrogen-bonding ability. The influence of a polarizable environment on the stability of the complexes has been investigated systematically with the dependence of the dielectric constant epsilon. With increasing epsilon, the complexes with S-containing ligands are more strongly stabilized than the complexes of the N-containing heterocycles. At epsilon = 78.4, the dielectric constant of water, 9-methylguanine remains the only purine derivative investigated which is competitive to neutral sulfur ligands. These findings are particularly important for a rationalization of the results from recent experimental studies on the competition of biological donor ligands L for coordination with the metal center of [Pt(dien)L](2+) (dien = 1,5-diamino 3-azapentane).